Results 161 to 170 of about 2,249 (191)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Ebglyss should not be reimbursed by public drug plans for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those ...
openaire +1 more source
Canada’s Drug Agency (CDA-AMC) recommends that Ebglyss should not be reimbursed by public drug plans for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those ...
openaire +1 more source
Lebrikizumab (Ebglyss) for Atopic Dermatitis
The Medical Letter on Drugs and TherapeuticsThe FDA has approved lebrikizumab-lbkz (Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg).
openaire +2 more sources
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
New England Journal of Medicine, 2023Brandon, Smith +2 more
openaire +2 more sources
Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review
Annals of PharmacotherapyBackground: Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment of moderate-to-severe AD in patients aged ≥12 years.
Danial Nasim +2 more
openaire +2 more sources
Lebrikizumab Monotherapy for the Treatment of Moderate to Severe Atopic Dermatitis
The Journal of Allergy and Clinical Immunology: In Practice, 2023Nikki, Kimura, Punita, Ponda
openaire +2 more sources
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Skin therapy letterAtopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that impacts approximately 10-15% of the population in the United States and Canada. Lebrikizumab is a novel systemic human monoclonal immunoglobulin G4 antibody that inhibits the activity of interleukin-13.
Leah, Johnston +2 more
openaire +1 more source
Lebrikizumab bei atopischer Dermatitis
DMW - Deutsche Medizinische Wochenschrift, 2023openaire +1 more source
<p>Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis</p>
Journal of Asthma and Allergy, 2020Tiffany Y Loh +2 more
exaly